Following a recent trial, doctors at The Christie Hospital are optimistic about the study of HMBD-001 in the treatment of ...

Bladder cancers comprise heterogeneous cell populations, and numerous factors are likely to be involved in dictating recurrence, progression and patient survival. While several molecular markers ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Ami Fadia, an analyst from Needham, maintained the Buy rating on Bicycle Therapeutics (BCYC – Research Report). The associated price target ...

Patients with muscle-invasive urothelial cancer face a high risk of relapse despite radical surgery and chemotherapy. The immune checkpoint inhibitor pembrolizumab may reduce this risk.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced data from its ...

Our study provides insight into the treatment landscape and outcomes for metastatic urothelial carcinoma in Mexico and highlights the need for improved access to novel therapies. These findings can ...

UroGen Pharma Ltd., a pioneering pharmaceutical company with a focus on innovative treatments for urothelial cancers, recently submitted an 8-K form to the Securities and Exchange Commission, ...

Duravelo-1 trial showed a 60% overall response rate for zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer. NECTIN4 gene amplification linked to higher response rates in ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...

China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.